Issue Navigation
-
Review
-
153-160
Laboratory diagnosis of COVID-19 in Africa: availability, challenges and implications
Oladipo EK, Ajayi AF, Odeyemi AN, Akindiya OE, Adebayo ET, Oguntomi AS, Oyewole MP, Jimah EM, Oladipo AA, Ariyo OE, Oladipo BB, Oloke JK
Drug Discov Ther. 2020; 14(4):153-160.
DOI: 10.5582/ddt.2020.03067
-
161-170
Association of ACE2 receptor and ACEIs/ARBs with disease severity in COVID-19
Sinha S, Sehgal A, Sehgal R
Drug Discov Ther. 2020; 14(4):161-170.
DOI: 10.5582/ddt.2020.03064
-
171-176
Review of current clinical management guidelines for COVID-19 with special reference to India
Kumar R, Vinod KS, Mittal A, Adhikari SD, Gupta N
Drug Discov Ther. 2020; 14(4):171-176.
DOI: 10.5582/ddt.2020.03059
-
177-180
A simple artificial diet available for research of silkworm disease models
Paudel A, Panthee S, Hamamoto H, Sekimizu K
Drug Discov Ther. 2020; 14(4):177-180.
DOI: 10.5582/ddt.2020.03061
-
181-186
Luo XL, Luo PD, Zhang YS
Drug Discov Ther. 2020; 14(4):181-186.
DOI: 10.5582/ddt.2020.01010
-
187-196
Wang TT, Sun ZG, Wang Y, Li FF, Zhou XM, Tian XS, Wang SQ
Drug Discov Ther. 2020; 14(4):187-196.
DOI: 10.5582/ddt.2020.03062
-
197-203
Lv ZY, Wang S, Zhao WD, He NN
Drug Discov Ther. 2020; 14(4):197-203.
DOI: 10.5582/ddt.2020.03058
-
204-208
Phenotypic analysis of human CYP2C9 polymorphisms using fluorine-substituted tolbutamide
Kitamura Y, Saeki K
Drug Discov Ther. 2020; 14(4):204-208.
DOI: 10.5582/ddt.2020.03060
-
209-210
Kanako S, Ikko K, Masatoshi J, Ihn H
Drug Discov Ther. 2020; 14(4):209-210.
DOI: 10.5582/ddt.2020.03065
-
211-212
Choosing the therapy for neurological infection with rapidly growing mycobacteria
Dash A, Gupta N, Ray Y, Kodan P, Singh BK, Soneja M
Drug Discov Ther. 2020; 14(4):211-212.
DOI: 10.5582/ddt.2020.03026